Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Core Viewpoint - Akebia Therapeutics, Inc. has initiated an underwritten public offering of its common stock, with the potential for underwriters to purchase an additional 15% of shares sold in the offering [1][2]. Group 1: Offering Details - The offering is being conducted under a shelf registration statement filed with the SEC on September 3, 2024, and declared effective on September 12, 2024 [2]. - A preliminary prospectus supplement detailing the terms of the offering is expected to be filed with the SEC [3]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1][6]. Group 2: Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [5].